APA (7th ed.) Citation

H, K., TW, N., I, J., M, K., S, P., CH, K., & K, J. (2026). Proarrhythmic Risk Assessment of Sildenafil under High-Dose Misuse Conditions Using the Comprehensive In Vitro Proarrhythmia Assay (CiPA). Biomolecules & therapeutics, 34(3), 578. https://doi.org/10.4062/biomolther.2025.097

Chicago Style (17th ed.) Citation

H, Kim, Na TW, Jung I, Kang M, Park S, Kwon CH, and Jung K. "Proarrhythmic Risk Assessment of Sildenafil Under High-Dose Misuse Conditions Using the Comprehensive In Vitro Proarrhythmia Assay (CiPA)." Biomolecules & Therapeutics 34, no. 3 (2026): 578. https://doi.org/10.4062/biomolther.2025.097.

MLA (9th ed.) Citation

H, Kim, et al. "Proarrhythmic Risk Assessment of Sildenafil Under High-Dose Misuse Conditions Using the Comprehensive In Vitro Proarrhythmia Assay (CiPA)." Biomolecules & Therapeutics, vol. 34, no. 3, 2026, p. 578, https://doi.org/10.4062/biomolther.2025.097.